US Senator Elizabeth Warren has asked the US Federal Trade Commission to "carefully scrutinize" the $16.5 billion bid by Novo Nordisk's (NVO) parent company for contract drug maker Catalent (CTLT) and to block the deal if it's found to be in breach of antitrust rules.
"I am concerned that this deal could increase Novo Nordisk's dominance over vital GLP-1 inhibitor drugs, reducing competition and increasing prices for patients," Warren said in a letter to FTC Chair Lina Khan.
Warren said that Eli Lilly (LLY) -- Novo Nordisk's largest rival in the market for GLP-1 weight loss and diabetes drugs -- "also contracts with Catalent to fill and package its drugs at Catalent sites."
"I am concerned that Novo Nordisk's merger with Catalent will give Novo Nordisk unprecedented visibility into and control over its competitor's production capacity, costs, and business practices, and the ability to preference its own products and obstruct its competitors' use of Catalent to produce GLP-1 drugs," Warren said in the letter.
Novo Nordisk and Catalent didn't immediately respond to requests for comment by MT Newswires.
Price: 117.62, Change: +0.62, Percent Change: +0.53
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。